Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799485 · ClinicalTrials.gov registry record · Phase 2
sEphB4-HSA in Treating Patients With Kaposi Sarcoma
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT02799485 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 23 participants.
The verdict
NCT02799485, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Recombinant EphB4-HSA Fusion Protein
- BEHAVIORAL Quality-of-Life Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-02-13 |
| Est. Completion | 2025-02-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02799485
The ClinicalTrials.gov registry entry for NCT02799485 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02799485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02799485 about?
NCT02799485 is a clinical study titled "sEphB4-HSA in Treating Patients With Kaposi Sarcoma". This phase II trial studies recombinant EphB4-HSA fusion protein (EphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.
What is the current status of trial NCT02799485?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-02-13. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT02799485?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL), Quality-of-Life Assessment (BEHAVIORAL).
Who is sponsoring clinical trial NCT02799485?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.